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Abstract
Antivenoms developed from the plasma of hyperimmunized animals are the only effective
treatment available against snakebite envenomation but shortage of supply contributes to the high
morbidity and mortality toll of this tropical disease. We describe a synthetic biology approach to
affordable and cost-effective antivenom production based on plant-made recombinant polyclonal
antibodies (termed pluribodies). The strategy takes advantage of virus superinfection exclusion to
induce the formation of somatic expression mosaics in agroinfiltrated plants, which enables the
expression of complex antibody repertoires in a highly reproduciblemanner. Pluribodies developed
using toxin-binding genetic information captured from peripheral blood lymphocytes of
hyperimmunized camels recapitulated the overall binding activity of the immune response.
Furthermore, an improved plant-made antivenom (plantivenom) was formulated using an in vitro
selected pluribody against Bothrops asper snake venom toxins and has been shown to neutralize a
wide range of toxin activities and provide protection against lethal venom doses in mice.
Introduction
Passive immunization (PI) with polyclonal antibodies (pAbs)
purified from animal serum was first adopted to treat diphtheria
in the 19th century (Graham and Ambrosino, 2015). Antibiotics
and monoclonal antibodies have progressively substituted antis-
era-based therapies. However, pAbs-based antivenoms remain
the only available treatment against complex toxin mixtures such
as those present in snake venoms. The global venom burden has
been estimated at 2.5 million envenomings and 125 000 deaths
per year (Chippaux, 1998). Despite steady improvements (Gutier-
rez, 2014b; Gutierrez et al., 2011), antivenom-based snakebite
treatments are not free of side effects as a consequence of the
exposure to heterologous antibody constant regions. Further-
more, antivenom supply is at constant risk due to high manufac-
turing costs and the low income level of target populations
(Arnold, 2016; Harrison et al., 2009). Antivenoms made of
recombinant human or humanized antibody cocktails would be
a highly desirable alternative as they would reduce the adverse
effects while facilitating product standardization and repro-
ducibility. Unfortunately, manufacturing costs for complex anti-
body cocktails are still high because to ensure consistency they
often require parallel production lines for each component of the
cocktail. Conversely, simplifying the cocktail composition may
compromise its efficacy due to the high diversity of toxins
comprising venoms. Furthermore, it is difficult to reconcile moves
towards cocktail simplification with a major trend in antivenom
formulation, namely to widen the spectrum of snake venoms
covered by a single treatment (Lavonas, 2012; Stock et al., 2007).
To overcome these limitations, we have developed a synthetic
biology strategy for antivenom production based on the expres-
sion of recombinant pAbs in plants. Plant biofactories provide
affordable alternative platforms for recombinant antibody pro-
duction (usually known as ‘plantibodies’) (Stoger et al., 2002) due
to their scalability, high production yields, the low risk of
contamination with adventitious pathogens and lower require-
ments for production facility building (Paul and Ma, 2011; Paul
et al., 2015). Our proposed strategy uses the plant chassis as a
production platform and takes advantage of an intrinsic property
of many plant viruses known as superinfection exclusion (SE) to
ensure reproducibility. SE prevents the superinfection of cells by a
second virus when they are already infected with a closely related
resident virus (Julve et al., 2013; Soller and Epstein, 1965; Syller,
2012). An important consequence of SE is the fact that
population variants in plant virus infections are not uniformly
distributed but structured in a mosaic-like pattern. Most
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importantly, this distribution ensures the maintenance and
propagation of population diversity as compared to the fitness-
driven quasispecies-like distributions typical of unstructured
population dynamics (Elena et al., 2011). We have investigated
the use of virus-based expression systems for the induction of
somatic expression mosaics in plant leaves, where each ‘tile’ in
the mosaic functions as an independent monoclonal micro-
production line, together leading to the production of recombi-
nant polyclonal cocktails. In this study, we show how this strategy
ensures the simultaneous production of high yields of recombi-
nant pAbs comprising hundreds of idiotypes with outstanding
batch-to-batch reproducibility, independently of the complexity
of the polyclonal composition. Most importantly, we show that
this novel strategy enables the expression of a selected portion of
a mammalian immunized antibody repertoire in a transiently
multitransgenic plant in a highly reproducible manner. We also
show that this strategy can be used to synthetize a complex plant-
made antibody cocktail able to neutralize a wide range of toxins
in the Bothrops asper venom – medically the most important
snake in Central America (Gutierrez, 2014a) – thus opening the
door to the formulation of efficient and affordable plant-made
recombinant antivenoms.
Results
Characterization of somatic expression mosaics in
Nicotiana benthamiana
The spatio-temporal dynamics of the mosaic-like expression
patterns were monitored in Nicotiana benthamiana leaves after
agroinfiltration of three virus-based infective clones encoding
GFP, BFP and DsRed fluorescent proteins (Figure 1a). To better
understand the dynamics of mosaic formation, we created a 2D
computer simulation in NetLogo (see Figure 1b and supporting
information) and compared the predicted computer outputs with
the experimental mosaic patterns obtained by the simultaneous
agroinfiltration of three viral clones encoding fluorescent pro-
teins. Based on the computer simulations, we anticipated that, for
a given set of initial parameters, mosaic (colour) composition
would be a highly reproducible outcome (Figure 1c) and that
reproducibility would increase with the number of initial infection
foci. Time-course co-infiltration analysis experimentally corrobo-
rated this prediction (Figure 1d). From these observations, we
hypothesized that the (mosaic) distribution pattern of viral clones
imposed by SE offers a competition-limited microenvironment
that ensures the survival of low-fitness clones. Moreover, with a
sufficiently high initial number of infective foci, SE will also
protect the systems from fluctuations in population dynamics,
providing highly reproducible outcomes.
Testing expression mosaics for the production of
recombinant pAbs: Pluribody technology
In a case study of a multiprotein plant biofactory, we attempted
to determine whether this platform could produce high yields of
recombinant antibody mixes while preserving the diversity of the
composition, ensuring high batch-to-batch reproducibility and
yielding a final product that was functionally equivalent to
traditional animal antivenom. To assess diversity preservation, we
first assayed the in planta expression of an antibody library
Figure 1 Principles of superinfection exclusion.
(a) N. benthamiana leaves showing somatic
expression mosaics produced by three magnICON
viral clones encoding DsRed, green and blue
florescent proteins agroinfected simultaneously at
OD600 = 0.01. Mosaics are observed either with
red/green filters for DsRed (left) or with UV light
(right). Below, detail of the mosaic in the framed
leaf area. (b) NetLogo computer simulation of a
triple viral co-infection (red, green and blue)
subjected to SE in a virtual area comprising
62 500 virtual cells. The virtual fitness (VF) for
each clone was adjusted to 1.0 : 1.0 : 0.7 (R:G:
B), and virtual OD600 (VOD) was adjusted to 300
(upper image) and 3000 (lower image) arbitrary
units to match the natural infection on (a, d) (see
Methods for detailed definitions of VF and VOD).
(c) Repeated NetLogo simulations of the evolution
of triple R-G-B infections using VOD values of 300
(up) and 3000 (down), respectively.
(d) Experimental data evolution of triple R-G-B
infections in N. benthamiana leaves were
performed at two different OD600 and recorded
daily up to day 7 postinfiltration. Evolution of
clone expansion is represented as percentage of
total leaf area occupied by each clone  SD.
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obtained from camel peripheral mononuclear blood cells (PMBC),
comprising a fraction of the antibody repertoire present in the
circulating B cells of an individual dromedary camel. Camel
antibodies were preferred because camelids display large immune
repertoires in single chain antibody format (Hcab), a feature that
greatly simplifies library construction and subsequent production
in plants using viral vectors. Hcab variable antibody regions were
PCR-amplified from PMBC cDNA and cloned en masse into the
pGVHH-His vector – a modified version of tobacco-mosaic virus
(TMV)-derived binary magnICON vector containing an in-frame
histidine tag for detection (Figure 2a) . The pGVHH-His library was
then mobilized to Agrobacterium tumefaciens cells and from here
to N. benthamiana leaves using vacuum agroinfiltration. After
7 days’ incubation, leaf apoplast fluid was recovered from
detached leaves and the VHH-His were purified by affinity
chromatography, resulting in a purified protein band of the
expected average size (15 kDa, Figure 2b). As anticipated, a two-
dimensional electrophoretic separation resolved the underlying
protein complexity and revealed a pattern of >200 distinguishable
spots, indicative of the polyclonal nature of the sample (Fig-
ure 2c). The resulting plant-made multiple recombinant antibody
products are hereafter referred to as pluribody samples. To
estimate the size of the repertoires that can be expressed using
this system, a GFP clone was co-infiltrated together with the
pGVHH-His library at different ratios. It was calculated that one
gram of fresh N. benthamiana leaves can produce up to 13 500
expression tiles using an Agrobacterium library inoculum at
OD600 = 0.1 (Figure 2c).
Pluribody technology ensures batch-to-batch
reproducibility
We then investigated the ability of the system to reproduce the
composition and reactivity of mammalian immune subrepertoires.
To this end, new antibody libraries in pGVHH-His were con-
structed starting from PBMC samples obtained from three
dromedary camels immunized with the same venom cocktail
derived from three snake species, Crotalus simus, Crotalus
scutulatus and Bothrops asper. To favour reproducibility and
ensure the preservation of the original diversity in any subsequent
analysis, the library construction procedure was standardized as
shown in Fig. S1 (detailed in Supplementary methods). Working
cell bank (WCB) aliquots were first used to evaluate the
production strategy in terms of reproducibility, by comparing
different VHH-His pluribody preparations. First, three pluribody
samples derived from the same immune repertoire but prepared
from different WCBs (PIM_1, PIM_2 and PIM_3) were labelled
with different fluorophores and resolved by 2D-DIGE analysis. The
almost perfect overlapping of DIGE images indicated that all three
complex protein samples were remarkably similar (Figure 3a). In a
separate DIGE experiment, two immune pluribodies (PIM_1 and
PIM_2) were compared with a third preparation derived from a
nonimmune repertoire (PPI_1). As the corresponding similarity
plots show (Figure 3b), the comparison of the protein spots from
equivalent immune pluribody samples (PIM_1 vs PIM_2) produced
a narrowly centred volume ratio distribution indicative of a highly
reproducible composition. In contrast, comparisons between
samples derived from different immune repertoires (PPI_1 vs
PIM_1; PPI_1 vs PIM_2) showed clear deviations in volume ratios.
Furthermore, deep sequencing of the CDR3 regions in VHH
mRNAs from agroinfiltrated plants showed the remarkable
conservation of sequence distribution between equivalent sam-
ples (PPI1 vs PPI2 and PIM1 vs PIM2), with only very minor
differences observed in the most abundant CDR3 sequences
(Figure 3c). Finally, when the venom-binding activities of PPI and
PIM samples were compared, the immune pluribodies consis-
tently showed reactivity against all three venoms employed for
Figure 2 Assessment of antiserum diversity.
(a) Schema of the cloning and transient expression
procedures used for the production of polyclonal
VHH antibodies. (b) First and second dimension
electrophoresis separation of VHH-His clones
purified from N. benthamiana leaves using Ni-
NTA affinity columns. (c) Expression of a GFP clone
as a viral subpopulation within a VHH -His library.
Images were taken after 10 dpi, and the average
tile size was recorded and used to estimate tile
density and its dependence with OD600 (right).
AttB, site-specific recombination site; SP, signal
peptide; NTR, nontranslated region; Tnos,
terminator of nopaline synthase.
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Figure 3 Assessment of pluribody reproducibility. (a) Individual and merged 2D DIGE images of three independent hyperimmune pluribody preparations in
VHH-His format (PIM_1, PIM_2 and PIM_3). (b) Comparison of the relative abundance of individual antibody clones in plant samples agroinfiltratedwith inocula
from independentWCBs derived from the sameMCB. Antibody clones were identified by deep sequencing of VHHCDR3 region. PPI_1 and PP_2 correspond to
equivalent pre-immune WCBs. PIM_1 and PIM_2 correspond to equivalent immune polyclonal WCBs. In each comparison, the same colours correspond to
identical antibody clones. (c). DIGE comparison of PPI and PIM purified pluribody preparations. Centred dots represent volume ratios close to one. (d) ELISA test
showing the venom-binding activity of three nonequivalent PIM preparations each obtained from a different individual camel and analysed against each of the
three venoms employed in the immunization. (e) Specificity test of PIM venom binding, comparing reactivity against Crotalus simus and cobra venoms.
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immunizations (Figure 3d), and no binding activity was observed
against BSA or nonrelated Naja venoms (Naja nubiae and Naja
mossambica) (Figure 3e).
Formulation of a snake plantivenom using Pluribody
technology
In contrast to traditional antivenoms obtained from hyperimmune
animal plasma, our pluribodies derive from PMBC pools. Hence,
the genetic information retrieved only corresponds to a minor
fraction of the reactive B cells made up of circulating memory
cells on their way to the bone marrow. Therefore, in order to
create a functional plant-made antivenom (hereafter termed
plantivenom), we decided to enrich our pluribody repertoires in
toxin binders by introducing an intermediate in vitro selection
step into the production flow chart (see Fig. S1). PCR-amplified
immune subrepertoires were first cloned in a phage display vector
and then subjected to three successive rounds of selection against
B. asper venom. To maximize diversity and avoid dominant
single-antigen selection bias, phage panning was conducted
against different fractions of the venom (four in total, roughly
corresponding to groups of toxin activities, Figure 4a). After
selection, all four sublibraries were pooled and the variable
antibody regions were amplified and transferred in bulk to the
pGVHH_IgGH1 vector (Figure 4b) carrying the constant regions of
human IgGH1 to create an enriched polyclonal (EP) master cell
bank (MCB) with increased reactivity and potentially less likely to
produce hypersensitivity reactions. EP_MCB was subsequently
distributed in WCBs and agroinfiltrated in N. benthamiana. The
PEP_1 formulation showed a 2xlog increase in total binding
activity when compared with the nonenriched pluribody in ELISA
(Figure 5A), demonstrating that enrichments in polyclonal com-
positions obtained by in vitro selection can be successfully
transferred to the plant, where they globally reproduce the
reactivity gains.
Finally, in order to produce the first iteration for a plantivenom
candidate, we decided to produce a pluribody incorporating 36
individual clones that showed maximum binding activities. The
clone composition of the resulting enriched oligoclonal formula-
tion (EO_1, see Fig. S1) is detailed as supplementary information
(Table S1). An EO_WCB was employed to scale up antibody
production using one kilogram of agroinfiltrated N. benthamiana
leaves and yielding 0.2 g of recombinant polyclonal antibody
collected from the corresponding leaf apoplastic fluid. Following
affinity purification (Figure 5A), an antivenom solution in PBS
(PEO_1) was prepared at a concentration of 46.5 mg protein/mL,
similar to the typical concentration of equivalent commercial
antivenoms (55 mg/mL), and used for further characterization
(summarized in Table 1). As expected, the PEO_1 solution
showed enriched antivenom-binding activity when assayed in
ELISA against B. asper venom (Figure 5B, C). Figure 5D showed
that phospholipases (PLA2), and to a lesser extent serine
proteinases (SP), P-I and P-III snake venom metalloproteinases
(SVMP) and L-amino acid oxidase (LAO) molecules, were effi-
ciently retained by the immobilized plantivenom. However, the
affinity matrix was poor in capturing disintegrins (DISI). Such
pattern of immunorecognition mirrors the immunological profile
of monospecific (B. asper) antivenoms (Gutierrez et al., 2010),
which were shown to quantitatively immunocapture most P-III
SVMPs, serine proteinases, L-amino acid oxidase, but only to a
lesser extent medium-sized disintegrins, PLA2 molecules, some
Figure 4 Strategy for pluribody formulation
enrichment. (a) Chromatographic profile and
electrophoresis separation of Bothrops asper
venom employed in antivenom pluribody
enrichment, showing the four groups of toxins
employed in phage display selection to reduce
antigen drift. (b) Cloning procedure for VHH
variable regions from PBMC cDNA to pHEN2-
derived pSword phage display vector and from
here to binary vector for plant expression adapted
from magnICON deconstructed system.
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serine proteinases and P-I SVMP BaP1. Later, the ability of PEO_1
to neutralize different B. asper toxic and enzymatic activities was
analysed. The PEO_1 plantivenom was able to neutralize venom
haemorrhagic, PLA2, proteinase and lethal activities (Table 1).
Figure 5C illustrates the neutralization of haemorrhagic activity in
the mouse skin test. The plantivenom did not neutralize in vitro
coagulant activity on plasma at the maximum concentration
tested (372 mg plantivenom/mg venom) (Table 1). Finally, we
tested the capacity of PEO_1 to neutralize lethality induced by
B. asper venom in mice, using 2 LD50s of venom as ‘challenge
dose’. PEO_1 prevented lethality in all injected mice at a ratio of
61.24 mg plantivenom/mg venom (supporting information) with
an estimated median effective dose (ED50) of 43 mg plantivenom/
mg venom (95% confidence limits: 33–56 mg/mg) (Table 1). All
PEO_1 neutralization activities were assayed in parallel with a
commercial horse-derived antivenom, and the corresponding
neutralizing activities are also summarized in Table 1. Horse-
derived antivenom was effective in the neutralization of all
enzymatic and toxic effects assayed.
Discussion
Global antivenom shortage has prompted several lines of research
aimed at finding solutions to the main production bottlenecks.
The use of immunization with DNA or with recombinant-
expressed epitopes of relevant toxins is an example of this,
aimed at circumventing the shortage of antigens in species with
low venom yield, such as coral snakes (Ramos et al., 2016). In
comparison, fully recombinant strategies can provide a more
satisfactory solution in the long term, addressing not only the
shortage of antigens, but also other problems arising from
current therapies such as adverse reactions and reproducibility
(Laustsen et al., 2016). In theory, rationally designed cocktail
formulations made of recombinant mAbs could outperform
animal plasma-derived antivenoms, as the composition of the
latter comprises a large fraction (≥80%) of immunologically
irrelevant antitoxin antibodies. In contrast, by adjusting the
antivenom composition to a minimal number of selected func-
tional components, the safety profile can be improved and
manufacturing costs can be reduced. Minimal recombinant
antibody cocktails comprising only three mAbs antibodies against
the main Bothrops toxins were shown to neutralize the lethal
toxicity of the venom (Frauches et al., 2013), indicating that
oligoclonal cocktails are suitable antivenom formulations at least
in some cases. Notwithstanding, a potent cocktail would probably
require more complex combinations, incorporating antibodies
against minor toxins, which could act alone or synergistically with
other toxins, to ensure the coverage of intra- and interspecific
Figure 5 Assessment of plantivenom functionality (A) Coomassie gel of an enriched oligoclonal plantivenom (PEO_1) production and purification steps:
lane1, crude apoplastic fluid; lane 2, leaf crude extract; lane 3 control apoplastic fluid from uninfected leaf; lane 4 clarified apoplastic fluid; lane 5, protein A
flow through; line 6, first wash; lanes 7 and 8, eluted plantivenom. (B) Comparison of ELISA binding activities against B. asper venom of sequential
plantivenom enrichment steps. PPI, pre-immune plantivenom; PIM, immune plantivenom; PEP, enriched polyclonal plantivenom derived from second and
third phage display selection rounds. (C) Comparison of binding activities between PEP and PEO_1. (D) Antivenomic profile of PEO_1 plantivenom. Upper
(a) and lower (b) panels display, respectively, chromatographic profiles of whole Costa Rican B. asper (Pacific population) venom, and the venom fraction
nonimmunoretained in the immobilized PEO_1 affinity column. (E) Neutralization of B. asper venom haemorrhagic activity in vivo with PEO_1 plantivenom
preparation (46.5 mg protein/mL). The figure shows the abdominal surface of mouse skin after 2-h injection with a constant dose of full venom and
different amounts of plantivenom. (a) haemorrhagic spot appearing in mice injected intradermally with 15 lg (5 MHD) of venom; (b) inhibition of 5 MHD
haemorrhagic spot with an antivenom dose of 250 lL PEO_1/mg venom; (c) 500 lL PEO_1/mg venom; (d) 750 lL PEO_1/mg venom; (e) negative control
(plantivenom diluted in PBS).
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variation. Complex cocktail composition imposes serious con-
straints on current manufacturing systems. Indeed, whereas the
formulation of improved cocktails seems an accessible objective
with current antibody selection techniques, the lack of suitable
production systems for these combinations has proved a practical
limitation, discouraging further advances. The pluribody strategy
is in line with other recent strategies based on mammalian cell
cultures aimed to produce affordable antibody cocktails (Laust-
sen, 2016; Rasmussen et al., 2012), which can foster the
development of improved recombinant formulations. The employ
of plant virus-based expression systems offers further advantages
associated with the use of plants as biofactories. As an example,
the deconstructed virus strategy (Marillonnet et al., 2004, 2005)
was successfully used to produce the Z-Mapp anti-Ebola protec-
tive antibody cocktail (Qiu et al., 2014) among other examples.
Record yields up to 4.8 g/kg FW of anti-idiotype antibodies have
been reported using magnICON (Bendandi et al., 2010). With our
current, nonoptimized yields, a 1000 sqm greenhouse facility
growing 15-kg biomass/m2/year (Walwyn et al., 2015) could
produce up to 3000 1.0 gram doses per year. Further improve-
ments in yield and formulation could reach 15 doses/m2/year as a
reasonable scenario.
The synthetic diversity offered by somatic mosaicism can be
exploited to quickly transfer ‘in mass’ large immune mammalian
subrepertoires, as exemplified with the PIM formulations.
Although faithful reproduction of the mammalian repertoire
cannot be guaranteed, we shown here that the antivenom-
binding profiles of large plant-made repertoires largely resemble
that of their corresponding antisera, and the same occurs during
the successive in vitro enrichment steps, indicating that any
possible expression bias does not affect substantially the binding
profile of the final product. In the future, sampling of lymphoid
organs and/or cell-sorting procedures could be incorporated to
enrich the composition of polyclonal mixtures. Alternatively,
additional in vitro selection steps as those shown here can be
used to refine composition, producing optimized oligoclonal
mixtures. In this line, the decision to conduct our final efficacy
tests with an oligoclonal formulation was taken with a double
objective: first to maximize diversity, as for some antigens late
phage display rounds could end up selecting strong monoclonal
binders only and second to facilitate the dissection of the
neutralization results, as the individual characterization of the
antibodies in the cocktail will facilitate improvements in subse-
quent formulations via incorporation of new (and distinct)
individual clones.
The PEO_1 cocktail described here showed a reasonable
spectrum of neutralizing activities with relatively little effort in
antibody selection; however, further efforts will be required to
reach efficacy levels of current commercial antivenoms. Enven-
omings by Bothrops asper are characterized by several patholog-
ical and pathophysiological alterations, among which alterations
in the coagulation are important. Thus, any antivenom to be
considered for use in envenomings by B. asper should be able to
neutralize the coagulant effect of the venom. This should prompt
further efforts to increase the neutralizing capacity of the
plantivenom and to generate neutralization of the coagulant
activity. With consistency and reproducibility ensured with the
pluribody strategy, the opportunities for formulation
improvements through the implementation of successive
design–build–test cycles are manifold. The neutralization of
coagulant activity can be improved with the introduction of
new serine protease neutralizing clones from improved antibody
selection procedures, synthetic repertoires or alternative single-
cell selection methods (Beerli and Rader, 2010). A streamlined
formulation should also involve the elimination of clones with
overlapping or non-neutralizing activities and, ultimately, the
incorporation of neutralizing activities against other snake ven-
oms from the same region. Our results should be followed by a
more in depth preclinical assessment of the plantivenom, using
various animal and in vitro models. Once a plantivenom with the
capacity to neutralize all toxic activities of the venom is
developed, the next step would be to consider the implementa-
tion of clinical trials and to stablish clinical doses. The dose of
antivenom to be administered in clinical cases cannot be directly
extrapolated from the preclinical neutralization tests. It has been
roughly estimated that an adult B. asper specimen may inject
50 mg of venom in a bite, although this varies from bite to bite
according to many variables (size of the snake, volume of venom
available in the gland, strength of the bite, etc.). Once an
antivenom has demonstrated efficacy in preclinical tests, clinical
trials involve an initial dose-finding phase, in which the optimal
dose of antivenom is selected. This dose is then used for more
extensive clinical trials with a higher number of patients.
The manipulation of SE for manufacturing purposes is pivotal in
the pluribody approach. SE ensures the independence of each
micro-production line, resulting in highly reproducible final prod-
ucts. The resulting structured population distribution simplifies the
modelling of the production process, as the whole system can be
regarded as the sum of thousands of independent micro-
production lines (expression tiles) working in parallel. This work
also underscores the potential of plant synthetic biology to offer the
world new bio-fabrication solutions. Pluribody technology combi-
nes genetic elements from biological sources as distant as camels,
humans and plant viruses to capture the immune repertoire of
hyperimmunized camels and recapitulate this within the plant
chassis, creating plantivenoms able to neutralize a wide range of
toxin activities that provideprotection against lethal venomdoses in
mice. Beyond antivenoms, we believe that the ability to formulate
pluribodies a la carte could provide a new boost to passive
immunotherapy, facilitating the formulation andmanufacturing of
new, affordable antitoxin and antimicrobial products.
Table 1 Neutralization of toxic activities of B. asper venom by
plantivenom and equine-derived antivenom
Toxic and enzymatic
activities of B. asper
venom
ED50 Plantivenom
(mg/mg venom)
ED50 Equine-derived
(mg/mg venom)
Haemorrhagic 22.2  0.65 6.9  0.01
Phospholipase A2 224.1  13.2 37.4  0.4
Proteolytic 120.5  4.2 43.0  2.0
Peritoneal lethality 43.2 (33.4–56.0) 3.1 (1.2–8.4)
Coagulant on
human plasma
≫372 11.3  0.13
Neutralization of haemorrhagic, phospholipase A2, proteinase and lethal
activities is expressed as median effective dose (ED50), whereas neutralization
of in vitro coagulant activity is expressed as effective dose (ED), in terms of mg
plantivenom or antivenom/mg venom protein (see Materials and methods for
details). Results are presented as mean  SD (n = 3) for neutralization of
haemorrhagic, phospholipase A2, proteinase and coagulant effects. In the case
of neutralization of lethal effect, the 95% confidence limits are included in
parenthesis.
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Materials and methods
Detailed information about the experimental methods can be
found in SI. All procedures involving experimental mice meet the
requirements of the Guiding Principles for Biomedical Research
Involving Animals (CIOMS, 1985) and were approved by the
Institutional Committee for the Care and Use of Laboratory
Animals of Universidad de Costa Rica (approval number 82-08).
The camel immunization protocol followed animal experimenta-
tion guidelines published by the regional government of the
Canary Islands (Spain) and was approved by the Ethics Commit-
tee, Veterinary Medicine Service, Las Palmas de Gran Canaria
University Foundation (Ref.: 009/2011)
Snake venoms and venom fractions
Venoms were obtained from specimens of B. asper, C. scutulatus
scutulatus and C. simus at the Serpentarium of the Instituto
Clodomiro Picado (University of Costa Rica, San Jose). For venom
fractionation, B. asper venom proteins were separated by
reverse-phase HPLC; the resolved chromatographic peaks (48)
were collected separately and the eluted fractions pooled in four
groups: group 1 was mainly composed of disintegrins; group 2 of
phospholipases; group 3 mainly contained serine proteases and
PLA2; and group 4 was enriched in metalloproteinases.
Camel immunization, total RNA isolation and
amplification of VHH sequences
Three camels (Camelus dromedarius) were immunized with a
cocktail containing equal amount of each of three snake venoms
(C. scutulatus, C. simus and B. asper). Peripheral blood lympho-
cytes (PBLs) obtained from ‘pre-immune’ and ‘immune’ samples
were used to isolate RNA and synthesize cDNA to be used as
template for PCR amplification of VHH coding sequences (see
supplementary materials and methods and Table S2 for the list of
primers used).
VHH Phage Display library construction and selection
The amplified VHH sequences were directly cloned as PCR
products into the pSword phagemid vector and the ligation
products transformed into E. coli. In a first round, venom binders
were selected using B. asper full venom as the antigen. Subse-
quent selection rounds were carried out separately against each
one of the four antigen groups obtained by venom fractionation.
Monitoring of the library enrichment was carried out by
polyclonal phage ELISA on B. asper full venom. Monoclonal
phage ELISA was carried out in the same way from individual
clones of the third round of selection; clones showing the highest
binding affinity for each individual antigen were selected to
formulate an oligoclonal mix: two clones from group 1; eight
from group 2; six from group 3; and 20 from group 4 (SI).
VHH plant expression libraries
VHH sequences amplified from PBL cDNA were directly cloned as
PCR products into pGVHH-His. Selected VHH phage display
libraries and individual clones were cloned in pGVHH-IgG vector.
pGVHH-His and pGVHH-IgG are adaptation of the magnICON
plant viral expression vector pICH7410 (ICON Genetics) built on a
pDGB1 vector backbone (Sarrion-Perdigones et al., 2011). Liga-
tion products were transformed into E. coli cells and plated on
solid LB agar plates. For libraries, bacteria were scraped and
stored in 1 mL aliquots as E. coli library stocks. One-tenth of the
library was used for plasmid DNA isolation. For individual clones, a
single colony was used to inoculate a fresh culture that was
afterwards used for plasmid DNA isolation, the remaining culture
being stored in 1 mL aliquots as E. coli glycerol stocks. The
isolated plasmid DNA was transformed into the Agrobacterium
tumefaciens GV3101 strain. The transformation was spread on LB
plates. Bacteria were scraped and stored in 500 lL aliquots as
library stocks to create a master cell bank (MCB). MCB aliquots
were grown O/N and distributed in working cell banks (WCB)
used for agroinfiltration.
Estimation of the polyclonal diversity of the somatic
mosaic
To determine average tile size in a typical polyclonal experiment, a
pGVHH-His antibody library was mixed with a pGGFP clone in
different ratios (1%, 5% and 10%) and co-infiltrated at different
OD600s (0.1, 0.03, 0.01 and 0.003) in N. benthamiana leaves.
Images of each experimental point taken at days 5 and 10 p.i
were analysed with ImageJ software (http://rsb.info.nih.gov/ij/),
and the number of tiles and average tile size were calculated
using the ‘Analyse particle’ function. An experimental surface/
weight conversion rate of 35.2 cm2/g FW in N. benthamiana
leaves was applied to calculate the number of expression tiles per
biomass.
Transient expression in Nicotiana benthamiana
For polyclonal and oligoclonal agroinfiltrations, an aliquot of the
WCB collection was used to inoculate an appropriate volume of
LB supplemented with antibiotics (1 : 250 subculture); cultures
were grown for 8 h at 28 °C. Cultures were collected by
centrifugation (10 min, 3000 g), re-suspended in agroinfiltration
medium (10 mM MES pH 5.6, 10 mM MgCl2, 200 lM acetosy-
ringone) to an optical density at 600 nm of 0.05 and incubated
for 2 h at room temperature on a horizontal rolling mixer. Before
infiltration, the bacterial suspensions harbouring VHH-6xHis or
VHH-Fc (3
0-provector modules) were mixed with equal volumes of
the pICH14011 (Integrase) and pICH17388 (50-provector module)
suspensions. For agroinfiltration, 5- to 6-week-old N. benthami-
ana plants were submerged in the agroinfiltration solution, a
vacuum was applied to a pressure of 0.9 bar (Vacuum
Degassing Chamber DP118, Applied Vacuum Engineering,
Thornbury, UK), held for 1 min and then slowly released. Samples
for protein extraction were collected 7–10 days postinfiltration.
Analysis of diversity and reproducibility at DNA level
Sequencing libraries were prepared from VHH-6xHis immune and
pre-immune library agroinfiltrated N. benthamiana leaves (see
supplementary materials and methods and Table S2 for the list of
primers used). Libraries were sequenced on an Ion Torrent PGM at
Life Sequencing (Valencia, Spain). Sequence quality trimming, de
novo assembly and posterior analysis were conducted using
custom Python scripts and iAssembler software (Zheng et al.,
2011). Unigenes composed of at least twomembers were used for
library comparison by BLASTN using the Blast User DB tool at http://
nbc11.biologie.uni-kl.de/.
Computer simulation of Somatic expression mosaics
Simulation of expression mosaic formation was performed with
NetLogo 6.0 agent-based modelling software (Wilensky, 1999),
with a script designed to simulate cell-to-cell movement of
exclusion-enabled viral clones on two-dimensional hexagonal grid
(Wilensky, 2007) (http://pgb.ibmcp.csic.es/netlogo/netlogo.html
and SI).
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Antivenomics
Affinity chromatography-based antivenomic (Pla et al., 2012) was
employed to address the immunocapturing ability of PEO_1
towards B. asper venom components. Columns were prepared by
immobilizing plantivenom on cyanogen bromide-activated
Sepharose 6 MB (SIGMA, St. Louis, USA), following the manu-
facturer’s instructions. The column was then loaded with B. asper
venom pooled from B. asper specimens from the Pacific versant
of Costa Rica. Bound and nonretained fractions were analysed by
HPLC. Chromatographic runs of whole B. asper venom dissolved
in PBS were used as controls.
Neutralization of toxic activities
The ability of plantivenom to neutralize proteinase, phospholipase
A2 (PLA2), hemorrhagic, coagulant, and lethal activities was
determined as previously described (Bolanos, 1972; Gene et al.,
1989; Gutierrez et al., 1985; Gutierrez et al., 1986; Gutierrez et
al., 2008; Theakston and Reid, 1983; Wang et al., 2004).
Neutralization was expressed as median effective dose (ED50) for
lethal, haemorrhagic, proteinase and PLA2 activities (plantivenom/
venom, or equine antivenom/venom, ratio in which the effect
was inhibited by 50% (Segura et al., 2010)), or as effective dose
(ED) for coagulant activity (the plantivenom/venom, or equine
antivenom/venom, ratio in which the clotting time was prolonged
three times as compared to venom incubated with PBS instead of
antibodies (Gene et al., 1989).
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